Kisspeptin-54
Also called Metastin
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Kisspeptin-54 IVF trigger trial
9.6 nmol/kg 36 hours before egg retrieval; randomized second dose or saline 10 hours later
Timed trigger and egg retrieval within an IVF cycle
Jayasena et al., Human Reproduction (2017) ↗When results may show
- When change was measured
- The endpoint was mature-oocyte yield, with subsequent reproductive follow-up—not a recurring libido or fertility supplement result.
- When to assess
- Timed trigger and egg retrieval within an IVF cycle
- Conditions and limitations
- 62 women at high risk of ovarian hyperstimulation during IVF. A tightly timed weight-based IVF trigger is not a daily or weekly home protocol. Kisspeptin-10 is not interchangeable.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Kisspeptin-54 describe 100–400 mcg per administration. Descriptive only, not a recommendation.
Modelled level — 3x per week
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 3/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Jayasena et al., Human Reproduction (2017)A tightly timed weight-based IVF trigger is not a daily or weekly home protocol. Kisspeptin-10 is not interchangeable.
Next steps
Kisspeptin-54 beginner guideOpen Kisspeptin-54 planning worksheetEstimate Kisspeptin-54 vial costTrack Kisspeptin-54 notes